Published in Br J Clin Pharmacol on October 01, 2013
Serelaxin in clinical development: past, present and future. Br J Pharmacol (2017) 0.81
Kidney remote ischemic preconditioning as a novel strategy to explore the accurate protective mechanisms underlying remote ischemic preconditioning. Interv Med Appl Sci (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
THE MEASUREMENT OF THE TUBULAR EXCRETORY MASS, EFFECTIVE BLOOD FLOW AND FILTRATION RATE IN THE NORMAL HUMAN KIDNEY. J Clin Invest (1938) 56.55
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med (2006) 20.27
Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol (2003) 9.08
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol (2006) 8.05
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis (2002) 7.03
Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis (2002) 6.52
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00
Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest (2005) 5.51
Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol (2004) 5.23
Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int (1985) 4.76
Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis (2000) 4.44
Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol (2005) 4.35
Mechanism and extent of distribution of inulin and sucrose in chloride space of tissues. Am J Physiol (1954) 3.77
Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis (2007) 3.53
Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol (2007) 3.48
Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int (2006) 3.48
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med (1983) 3.32
Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis (2005) 3.14
Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol (2008) 3.10
Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem (2005) 3.10
Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol (2009) 3.01
Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol (2009) 3.00
Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int (1995) 2.97
Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int (2012) 2.94
Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int (2007) 2.93
Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis (1990) 2.91
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol (1995) 2.73
Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med (2012) 2.69
Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol (2007) 2.63
Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut (1996) 2.63
Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem (1994) 2.62
CKD: common, harmful, and treatable--World Kidney Day 2007. Am J Kidney Dis (2007) 2.58
A rapid urine test for early detection of kidney injury. Kidney Int (2009) 2.50
Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int (2012) 2.46
Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis (2009) 2.43
Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol (2004) 2.43
Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant (2010) 2.41
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
How to measure renal function in clinical practice. BMJ (2006) 2.22
Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int (2007) 2.22
Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol (2007) 2.20
Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol (2006) 2.18
Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology (2010) 2.08
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis (2008) 2.05
Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology (2005) 2.02
COMPARISON OF THE CONSTANT INFUSION AND URINE COLLECTION TECHNIQUES FOR THE MEASUREMENT OF RENAL FUNCTION. J Clin Invest (1948) 2.01
High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation (2007) 2.01
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem (2005) 1.89
Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int (2008) 1.85
Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol (1975) 1.83
MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant (2005) 1.82
Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens (2008) 1.81
The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest (1985) 1.81
Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med (1984) 1.81
Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I-iothalamate. Kidney Int (1973) 1.80
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med (2005) 1.76
ENDOGENOUS-CREATININE CLEARANCE AND GLOMERULAR-FILTRATION RATE. Lancet (1964) 1.70
Measurement of kidney function. Med Clin North Am (2005) 1.65
Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand (1985) 1.65
Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Int (2005) 1.62
How should proteinuria be detected and measured? Ann Clin Biochem (2009) 1.58
Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis (2003) 1.49
Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol (2008) 1.46
How to assess glomerular function and damage in humans. J Hypertens (1999) 1.45
Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol (2011) 1.41
Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol (2012) 1.39
Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond) (1984) 1.36
Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol (1980) 1.36
Glomerular filtration rate measurement by "single-shot" injection of inulin. Kidney Int (1994) 1.30
The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care (1997) 1.28
The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant (2011) 1.26
Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem (2006) 1.22
Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. Hypertension (2006) 1.21
Diffusion-weighted MR imaging of kidneys in patients with chronic kidney disease: initial study. Eur Radiol (2009) 1.20
Assessing glomerular filtration rate in healthy Indian adults: a comparison of various prediction equations. J Nephrol (2005) 1.17
Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol (2007) 1.17
Cohort profile: the chronic kidney disease prognosis consortium. Int J Epidemiol (2012) 1.16
Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem (1998) 1.15
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension (2011) 1.15
The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl (2005) 1.13
The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis (1995) 1.12
Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res (2008) 1.12
Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease. Ann Clin Biochem (2009) 1.09
Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin Pract (2009) 1.09
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens (2008) 1.08
Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther (2007) 1.05
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
A prescription for better prescribing. BMJ (2006) 5.31
A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr (2007) 4.34
Clinical pharmacology--too young to die? Lancet (2006) 4.32
Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (2011) 4.06
Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates. Br J Clin Pharmacol (2008) 3.52
Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol (2003) 3.37
The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol (2004) 3.35
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol (2012) 3.15
Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension (2009) 2.38
A spoonful of sugar? Tomorrow's doctors 2002. Br J Clin Pharmacol (2002) 2.32
Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension (2006) 2.30
Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology (2013) 2.24
Management of paracetamol poisoning. BMJ (2011) 2.24
Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol (2006) 2.19
Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol (2002) 2.14
Nitric oxide regulates local arterial distensibility in vivo. Circulation (2002) 2.04
Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis (2011) 1.80
Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes (2006) 1.79
COX-2 selective inhibitors--important lessons learned. Lancet (2005) 1.74
Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med (2012) 1.70
Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens (2002) 1.66
Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. J Immunol (2011) 1.63
Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol (2012) 1.61
Perceived causes of prescribing errors by junior doctors in hospital inpatients: a study from the PROTECT programme. BMJ Qual Saf (2012) 1.61
Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctors. Implement Sci (2012) 1.60
Delayed DMSO administration protects the kidney from mercuric chloride-induced injury. J Am Soc Nephrol (2004) 1.60
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Impact on hypertension control of a patient-held guideline: a randomised controlled trial. Br J Gen Pract (2006) 1.56
Poor prescribing is continual. BMJ (2006) 1.55
Non-invasive measurement of cardiac output in patients with chronic heart failure. Blood Press Monit (2004) 1.51
Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem (2008) 1.48
Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis (2013) 1.47
Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol (2008) 1.47
A urine-concentrating defect in 11β-hydroxysteroid dehydrogenase type 2 null mice. Am J Physiol Renal Physiol (2012) 1.47
New guidelines for drive-by renal arteriography may lead to an unjustifiable increase in percutaneous intervention. Heart (2007) 1.46
Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. Cardiovasc Res (2012) 1.46
Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension (2009) 1.46
Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension (2010) 1.45
Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol (2002) 1.42
The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol (2006) 1.42
Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol (2004) 1.41
Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol (2002) 1.40
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40
Nitric oxide and the regulation of arterial elasticity: right idea, wrong vascular bed? Hypertension (2002) 1.38
Vascular effects of apelin in vivo in man. J Am Coll Cardiol (2008) 1.33
Strain and temperature sensitivity of a single-mode polymer optical fiber. Opt Lett (2005) 1.33
Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells. J Physiol (2011) 1.32
Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) (2006) 1.31
Quantification of human urinary exosomes by nanoparticle tracking analysis. J Physiol (2013) 1.31
Arterial stiffness and hypertension: emerging concepts. Hypertension (2009) 1.30
Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia (2005) 1.28
Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis (2013) 1.28
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 1.27
Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension (2006) 1.26
Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol (2005) 1.24
Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. Br J Clin Pharmacol (2014) 1.22
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology (2002) 1.18
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension (2011) 1.15
Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol (2007) 1.15
Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension (2008) 1.13
Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol (2006) 1.13
Understanding the pathophysiological regulatory role of microRNAs in acute liver failure. Hepatology (2015) 1.09
The road from AKI to CKD: the role of endothelin. Kidney Int (2013) 1.09
Impact of a focussed teaching programme on practical prescribing skills among final year medical students. Br J Clin Pharmacol (2011) 1.09
Limitations of AST/ALT ratio in paracetamol poisoning. Clin Toxicol (Phila) (2015) 1.08
Cardiovascular effects of acute oxygen administration in healthy adults. J Cardiovasc Pharmacol (2003) 1.08
Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol (2009) 1.06
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J Alzheimers Dis (2008) 1.05
Junior doctors' perceptions of their self-efficacy in prescribing, their prescribing errors and the possible causes of errors. Br J Clin Pharmacol (2013) 1.05
Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. Hypertension (2002) 1.03
Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab (2007) 1.02
Prognosis without treatment as a modifier in health economic assessments. BMJ (2005) 1.02
Continuous wave ultraviolet light-induced fiber Bragg gratings in few- and single-mode microstructured polymer optical fibers. Opt Lett (2005) 1.02
Nebivolol increases arterial distensibility in vivo. Hypertension (2004) 0.99
Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) (2006) 0.99
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig (2008) 0.97
Letter by Payne and Webb regarding article, "agreement among cardiovascular disease risk calculators". Circulation (2013) 0.97
Endothelium-derived endothelin-1. Pflugers Arch (2009) 0.97
Humidity insensitive TOPAS polymer fiber Bragg grating sensor. Opt Express (2011) 0.97
Quantitative 3-dimensional imaging of murine neointimal and atherosclerotic lesions by optical projection tomography. PLoS One (2011) 0.95
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res (2002) 0.95
Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci (2007) 0.93
Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs (2002) 0.93
Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension (2013) 0.92
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. Br J Clin Pharmacol (2008) 0.92
Oxygen therapy in acute medical care. BMJ (2002) 0.91
The application of mass-spectrometry-based protein biomarker discovery to theragnostics. Br J Clin Pharmacol (2010) 0.91
Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl (2003) 0.91